: Monday, May 10, 2021, 10:02 AM IST
Cipla ties up with US pharma Eli Lilly to make, sell Baricitinib for COVID-19 treatment in India
Cipla
Cipla Ltd has entered into a licensing agreement with American pharma company Eli Lilly to expand access to COVID-19 treatment in India.
The Mumbai-based company said it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for baricitinib.
In a filing, the firm said: Cipla Limited on Monday announced that it has entered into a licensing agreement with Eli Lilly to expand access to Covid-19 treatment in India. The pharma company has signed a royalty-free, non-exclusive voluntary licensing agreement with US Eli Lilly for the manufacture and commercialization of the drug Baricitinib for Covid-19 indication, it said in a filing to the stock exchanges.
Cipla rose 1.10% to Rs 898.50 after the drug major said it will distribute Roche s antibody cocktail (Casirivimab and Imdevimab) in India.
Roche India said that the Central Drugs Standards Control Organisation (CDSCO) has provided an Emergency Use Authorisation (EUA) for Roche s antibody cocktail (Casirivimab and Imdevimab) in India. The approval was based on the data that have been filed for the EUA in the United States, and the scientific opinion of the Committee for Medicinal Products for Human Use (CHMP) in the European Union.
The antibody cocktail is to be administered for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe COVID-19 disease.
Last Updated:
India Approves Roche s Antibody Cocktail COVID Treatment For Mild Cases; Trump Had Taken
The Central Drugs Standards Control Organisation (CDSCO) on Wednesday granted Emergency Use Authorisation (EUA) to Roche for the antibody cocktail.
Expanding its arsenal of drugs to battle the massive second wave of COVID-19, the Central Drugs Standards Control Organisation (CDSCO) on Wednesday granted Emergency Use Authorisation (EUA) to Swiss pharma company Roche for the antibody cocktail Casirivimab and Imdevimab in India. The decision was taken based on data filed with the U.S. regulators and the scientific opinion of a European regulatory panel.
Confirming the news, Roche Pharma India MD V Simpson Emmanuel said, With the increasing number of COVID-19 infections in India, Roche is committed to doing everything we can to minimize hospitalizations and ease pressure on healthcare systems, He added, This is where neutralizing antibody cocktails like Casirivima
Updated:
May 05, 2021 20:18 IST
This will enable Roche to import the globally manufactured product batches to India where it has a partnership with Cipla to market as well as distribute the same
Share Article
AAA
The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland. | Photo Credit:
Reuters
This will enable Roche to import the globally manufactured product batches to India where it has a partnership with Cipla to market as well as distribute the same
Roche India on Wednesday said it has received emergency use authorisation (EUA) of the Central Drugs Standards Control Organisation for antibody cocktail (Casirivimab and Imdevimab) that is indicated for treatment of mild to moderate COVID-19.
Cipla MD and Global CEO Umang Vohra said, This partnership with Roche is a significant step in enabling access to promising treatments in furtherance to our purpose of Caring for Life .